


Company Registration No. 00934139

Azelis UK Life Sciences Limited

Report and Unaudited Financial Statements

for the year ended 31 December 2020



Azelis UK Life Sciences Limited
Report and unaudited financial statements 2020

Contents	Page
Officers and professional advisers	1
Strategic report	2
Directors' report	3
Statement of directors' responsibilities	4
Balance sheet	5
Notes to the financial statements	6

Azelis UK Life Sciences Limited
Company Registration No. 00934139

Report and financial statements 2020

Officers and professional advisers

Directors

J T Traynor
T Bakker
A Bertona
S E Roberts

Secretary

S E Roberts

Registered Office

Axis House
Tudor Road
Manor Park
Runcorn
WA7 1B

Azelis UK Life Sciences Limited
Company Registration No. 00934139

Strategic report

Principal activity

The company ceased trading in 2018 and has not traded during the year.

Business Review

Following the transfer of all trade and assets to a fellow group undertakings on 1st January 2018 the company ceased trading with effect from that date.

Approved by the Board of Directors
and signed on behalf of the Board


S E Roberts
Director

16th September 2021

Directors' report

The directors present their report and the financial statements for the year ended 31st December 2020.

Going concern

The Company ceased trading in 2018. As such, these financial statements have been prepared on a basis other than that of a going concern. No material adjustments arose as a result of ceasing to apply the going concern basis.

Directors

The director who served during the period were:

J T Traynor
T Bakker
A Bertona
S E Roberts

Approved by the Board and signed on its behalf by

A handwritten signature in black ink, appearing to read 'S. Roberts', is written over a horizontal line.

S E Roberts
Director

16th September 2021

Statement of directors' responsibilities

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulation.


Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have prepared the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 102 "The Financial Reporting Standard Applicable in the UK and Republic of Ireland", and applicable law).

Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing the financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- state whether applicable United Kingdom Accounting Standards, comprising FRS 102, have been followed, subject to any material departures disclosed and explained in the financial statements;
- make judgements and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006.



S E Roberts
Director

16th September 2021

Azelis UK Life Sciences Limited
Company Registration No. 00934139

Balance sheet
As at 31 December 2020

	Note	2020 £'000	2019 £'000
Current assets			
Debtors	4	1,576	1,576
		<u>1,576</u>	<u>1,576</u>
Creditors: amounts falling due within one year	5	(1,057)	(1,057)
		<u>(1,057)</u>	<u>(1,057)</u>
Net current assets		<u>519</u>	<u>519</u>
Net assets		<u>519</u>	<u>519</u>
Called up share capital	6	115	115
Share premium account	7	404	404
		<u>519</u>	<u>519</u>
Total shareholders' funds		<u>519</u>	<u>519</u>

For the year ended 31st December 2020 the company was entitled to an exemption from an audit under section 480 of the Companies Act 2006 relating to dormant companies.


The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibility for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements of Azelis UK Life Sciences Limited (company registration no. 00934139) were approved by the Board and authorised for issue 16th September 2021

Signed on behalf of the Board of Directors



S E Roberts
Director

Notes to the financial statements

For the year ended 31 December 2020

1. General Information

Azelis UK Life Sciences Limited is a private company limited by shares, incorporated in the United Kingdom and registered in England & Wales. The registered office is Axis House, Tudor Road, Manor park, Runcorn, Great Britain, WA7 1BD.

2. Statement of compliance

The financial statements of Azelis UK Life Sciences Limited have been prepared in compliance with United Kingdom Accounting Standards, including Financial Reporting Standard 102, "The Financial Reporting Standard Applicable in the United Kingdom and the Republic of Ireland" ("FRS 102") and the Companies Act 2006.

3. Summary of significant accounting policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

(a) Basis of Preparation

The financial statements have been prepared under the historical cost convention and in accordance with applicable United Kingdom accounting standards.

(b) Going concern

The Company is dormant. As such, these financial statements have been prepared on a basis other than that of a going concern. No material adjustments arose as a result of ceasing to apply the going concern basis.

(c) Exemptions for qualifying entities under FRS 102

FRS 102 allows a qualifying entity certain disclosure exemptions, subject to certain conditions, which have been complied with, including notification of, and no objection to, the use of exemptions by the company's shareholders.

The company has taken advantage of the following exemptions:

- (i)** From preparing a Statement of Cash Flows, on the basis that it is a qualifying entity and the group consolidated financial statements include a Statement of Cash Flow
- (ii)** Group Related Party disclosures for 100% subsidiaries within the group
- (iii)** Key management personnel
- (iv)** Financial instruments

Notes to the financial statements

For the year ended 31 December 2020

3. Summary of significant accounting policies (continued)

(d) Financial instruments

The company has chosen to adopt Sections 11 and 12 of FRS 102 in respect of financial instruments.

(i) Financial assets

Basic financial assets, including trade and other receivables, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

(ii) Financial liabilities

Basic financial liabilities, including trade and other payables, bank loans and loans from fellow Group companies that are classified as debt, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

(e) Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

4. Debtors

	2020	2019
	£'000	£'000
Amounts owed by group undertakings	1,576	1,576
	<u>1,576</u>	<u>1,576</u>

Amounts owed by group undertakings are loans which are unsecured, repayable on demand and are interest free.

Azelis UK Life Sciences Limited
Company Registration No. 00934139

Notes to the financial statements
For the year ended 31 December 2020

5. Creditors: amounts falling due within one year

	2020 £'000	2019 £'000
Amounts owed to group undertakings	1,057	1,057
	<u>1,057</u>	<u>1,057</u>

Amounts owed to group undertakings are unsecured, repayable on demand and are interest free.

6. Called up share capital

	2020 £'000	2019 £'000
Authorised		
115,000 Ordinary shares of £1 each	115	115
	<u>115</u>	<u>115</u>
Allotted, called up and fully paid		
115,000 Ordinary shares of £1 each	115	115
	<u>115</u>	<u>115</u>

7. Reserves

Called up share capital represents the nominal value of shares that have been issued.

Share premium account includes any premiums received on issue of share capital. Any transaction costs associated with the issuing of shares are deducted from share premium.

Profit and loss account includes all current and prior year retained profits and losses.

8. Controlling interest

The company's immediate parent undertaking is Azelis UK Holdings Limited. Azelis Holding Sarl is the ultimate parent company and controlling party.

Azelis Holding Sarl is the only member of the group which prepares consolidated financial statements. The consolidated financial statements of Azelis Holding Sarl are available to the public and may be obtained from the company's registered address.